Literature DB >> 23215542

Corneal inflammation is inhibited by the LFA-1 antagonist, lifitegrast (SAR 1118).

Yan Sun1, Rui Zhang, Thomas R Gadek, Charles A O'Neill, Eric Pearlman.   

Abstract

PURPOSE: Sterile corneal infiltrates can cause pain, blurred vision, and ocular discomfort in silicone hydrogel contact-lens users. The current study investigates the potential for the synthetic lymphocyte functional antigen-1 (LFA-1) antagonist lifitegrast (SAR 1118) to block corneal inflammation using a murine model.
METHODS: The role of LFA-1 (CD11a/CD18) was examined either in CD18(-/-) mice, by intraperitoneal injection of anti-CD11a, or by topical application of lifitegrast. Corneal inflammation was induced by epithelial abrasion and exposure to either tobramycin-killed Pseudomonas aeruginosa or Staphylococcus aureus in the presence of a 2-mm-diameter punch from a silicone hydrogel contact lens. After 24 h, corneal thickness and haze were examined by in vivo confocal microscopy, and neutrophil recruitment to the corneal stroma was detected by immunohistochemistry.
RESULTS: Neutrophil recruitment to the corneal stroma and development of stromal haze were significantly impaired in CD18(-/-) mice or after injection of anti-CD11a. Topical lifitegrast also inhibited P. aeruginosa- and S. aureus-induced inflammation, with the optimal application being a 1% solution applied either 2 or 3 times prior.
CONCLUSION: As LFA-1-dependent neutrophil recruitment to the corneal stroma can be blocked by topical lifitegrast, this reagent could be used in combination with antibiotics to prevent leukocyte infiltration to the corneal stroma in association with contact-lens wear.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23215542      PMCID: PMC3643258          DOI: 10.1089/jop.2012.0102

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.671


  35 in total

1.  Risk factors for corneal infiltrative events during continuous wear of silicone hydrogel contact lenses.

Authors:  Loretta Szczotka-Flynn; Jonathan H Lass; Ajay Sethi; Sara Debanne; Beth Ann Benetz; Matthew Albright; Beth Gillespie; Jana Kuo; Michael R Jacobs; Alfred Rimm
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-06-10       Impact factor: 4.799

2.  Delivery of SAR 1118 to the retina via ophthalmic drops and its effectiveness in a rat streptozotocin (STZ) model of diabetic retinopathy (DR).

Authors:  Vidhya R Rao; Elizabeth Prescott; Namdev B Shelke; Ruchit Trivedi; Peter Thomas; Craig Struble; Tom Gadek; Charles A O'Neill; Uday B Kompella
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-05-05       Impact factor: 4.799

3.  Safety and pharmacokinetics of a novel lymphocyte function-associated antigen-1 antagonist ophthalmic solution (SAR 1118) in healthy adults.

Authors:  Charles P Semba; Dennis Swearingen; Valerie L Smith; Mary S Newman; Charles A O'Neill; John P Burnier; David B Haughey; Thomas R Gadek
Journal:  J Ocul Pharmacol Ther       Date:  2010-03-24       Impact factor: 2.671

4.  The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.

Authors:  Christopher J Murphy; Ellison Bentley; Paul E Miller; Kim McIntyre; Gary Leatherberry; Richard Dubielzig; Elizabeth Giuliano; Cecil P Moore; Thomas E Phillips; Peter B Smith; Elizabeth Prescott; Jacqueline M Miller; Peter Thomas; Randall Scagliotti; Doug Esson; Tom Gadek; Charles A O'Neill
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-16       Impact factor: 4.799

5.  TLR4 and TLR5 on corneal macrophages regulate Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -independent pathways.

Authors:  Yan Sun; Mausita Karmakar; Sanhita Roy; Raniyah T Ramadan; Susan R Williams; Scott Howell; Carey L Shive; Yiping Han; Charles M Stopford; Arne Rietsch; Eric Pearlman
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

6.  ICAM-1 mediates surface contact between neutrophils and keratocytes following corneal epithelial abrasion in the mouse.

Authors:  Debjani Gagen; Sara Laubinger; Zhijie Li; Matei S Petrescu; Evelyn S Brown; C Wayne Smith; Alan R Burns
Journal:  Exp Eye Res       Date:  2010-08-14       Impact factor: 3.467

Review 7.  Microbial contamination of contact lenses, lens care solutions, and their accessories: a literature review.

Authors:  Loretta B Szczotka-Flynn; Eric Pearlman; Mahmoud Ghannoum
Journal:  Eye Contact Lens       Date:  2010-03       Impact factor: 2.018

Review 8.  Toll-like receptors at the ocular surface.

Authors:  Eric Pearlman; Angela Johnson; Gautam Adhikary; Yan Sun; Holly R Chinnery; Todd Fox; Mark Kester; Paul G McMenamin
Journal:  Ocul Surf       Date:  2008-07       Impact factor: 5.033

9.  Regulation of endotoxin-induced keratitis by PECAM-1, MIP-2, and toll-like receptor 4.

Authors:  Saloni Khatri; Jonathan H Lass; Fred P Heinzel; W Matthew Petroll; John Gomez; Eugenia Diaconu; Carolyn M Kalsow; Eric Pearlman
Journal:  Invest Ophthalmol Vis Sci       Date:  2002-07       Impact factor: 4.799

10.  Inhibition of corneal inflammation by the TLR4 antagonist Eritoran tetrasodium (E5564).

Authors:  Yan Sun; Eric Pearlman
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-20       Impact factor: 4.799

View more
  12 in total

1.  Inhibition of Corneal Inflammation by the Resolvin E1.

Authors:  Ji-Eun Lee; Yan Sun; Per Gjorstrup; Eric Pearlman
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-04       Impact factor: 4.799

Review 2.  Lifitegrast Ophthalmic Solution 5%: A Review in Dry Eye Disease.

Authors:  Gillian M Keating
Journal:  Drugs       Date:  2017-02       Impact factor: 9.546

3.  Improving Tolerance and Compliance with Topical Immunomodulators Using Micro-Emulsion Lipid Layer Artificial Tears.

Authors:  Alice T Epitropoulos; Anthony Therattil; Laura M Periman; Eric D Rosenberg
Journal:  Clin Ophthalmol       Date:  2020-07-06

Review 4.  Host defense at the ocular surface.

Authors:  Eric Pearlman; Yan Sun; Sanhita Roy; Mausita Karmakar; Amy G Hise; Loretta Szczotka-Flynn; Mahmoud Ghannoum; Holly R Chinnery; Paul G McMenamin; Arne Rietsch
Journal:  Int Rev Immunol       Date:  2013-02       Impact factor: 5.311

5.  Safety of Lifitegrast Ophthalmic Solution 5.0% in Patients With Dry Eye Disease: A 1-Year, Multicenter, Randomized, Placebo-Controlled Study.

Authors:  Eric D Donnenfeld; Paul M Karpecki; Parag A Majmudar; Kelly K Nichols; Aparna Raychaudhuri; Monica Roy; Charles P Semba
Journal:  Cornea       Date:  2016-06       Impact factor: 2.651

Review 6.  The Pathogenesis of Staphylococcus aureus Eye Infections.

Authors:  Richard J O'Callaghan
Journal:  Pathogens       Date:  2018-01-10

7.  SIDRE: Symptomatic Improvement of Dry Eye Study.

Authors:  Clarissa J De Paz; Agustin L Gonzalez; Chi Ngo
Journal:  Clin Optom (Auckl)       Date:  2017-03-16

8.  Safety and efficacy of lifitegrast 5% ophthalmic solution in contact lens discomfort.

Authors:  Agustin L Gonzalez
Journal:  Clin Ophthalmol       Date:  2018-10-16

Review 9.  Dry eye syndrome: developments and lifitegrast in perspective.

Authors:  Ivonne V Lollett; Anat Galor
Journal:  Clin Ophthalmol       Date:  2018-01-15

Review 10.  The Immunological Basis of Dry Eye Disease and Current Topical Treatment Options.

Authors:  Laura M Periman; Victor L Perez; Daniel R Saban; Meng C Lin; Piergiorgio Neri
Journal:  J Ocul Pharmacol Ther       Date:  2020-03-12       Impact factor: 2.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.